BiotechTube
ViferaXS

ViferaXS

Munich, Germany· Est.
viferaxs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ViferaXS is a Munich-based biotech founded in 2018, developing 'Dual Force' off-the-shelf immunotherapies for cancer. Its core technology platform rapidly identifies naturally presented tumor antigens from patient samples and pairs them with a proprietary adjuvant, XS15, to induce potent T-cell responses. The company has a Phase II-ready program in Chronic Lymphocytic Leukemia (CLL) and is seeking partnerships to advance its pipeline in hematologic and solid tumors.

Oncology

Technology Platform

Proprietary 'Dual Force' platform combining an immunopeptidome-based antigen discovery engine (identifying naturally presented tumor antigens) with a superior adjuvant formulation (XS15) to create off-the-shelf, peptide-based T cell activators.

Opportunities

The growing demand for scalable, effective cancer immunotherapies presents a massive market opportunity.
ViferaXS's off-the-shelf approach, if clinically validated, could offer a faster and potentially more cost-effective alternative to fully personalized vaccines, making it attractive for partnerships and commercialization.
The platform's applicability to both hematologic and solid tumors broadens its potential impact.

Risk Factors

Key risks include clinical failure of its lead CLL program or other pipeline candidates, which is inherent in drug development.
As a private, pre-revenue company, it faces significant funding risk and depends on securing partnerships or further investment.
There is also intense competition in the cancer vaccine and immuno-oncology space from larger, well-funded entities.

Competitive Landscape

ViferaXS competes in the crowded cancer immunotherapy space, facing competition from personalized neoantigen vaccine companies (e.g., BioNTech, Moderna in oncology), other peptide vaccine developers, and broader modalities like cell therapies and checkpoint inhibitors. Its key differentiation is the off-the-shelf use of directly identified, naturally presented antigens combined with a proprietary adjuvant, aiming for a balance between personalization and scalability.

More companies in Immunotherapy / Immuno-Oncology →More companies in Germany →